This document These recommendations provides guidance for the responsible and prudent use of antimicrobial agents in veterinary medicine, with the aim of protecting both animal and human health as well as the environment. It defines the respective responsabilities of the Competent Authority and stakeholders involved in the authorisation, production, control, distribution and use of veterinary medicinal products (VMP) containing antimicrobial agent(s) such as the national regulatory authority, the veterinary pharmaceutical industry, veterinarians, animal feed manufacturers, distributors and food animal producers who are involved in the authorisation, production, control, importation, exportation, distribution and use of veterinary medicinal products (VMP) containing antimicrobial agent(s). The Competent Authorities responsible for the registration and control of all groups involved in the authorisation production, distribution and use of veterinary antimicrobials have specific obligations.
. prevent or reduce the transfer of resistant micro-organisms or resistance determinants from animals to humans;
64) contribute to maintaining the efficacy and usefulness of antimicrobial agents used in animal and human medicine and prolong the usefulness of the antimicrobials;
7. prevent the contamination of animal-derived food with antimicrobial residues that exceed the established maximum residue limit (MRL); 85) protect consumer health by ensuring the safety of food of animal origin with respect to residues of antimicrobial agents drugs, and the ability to transfer antimicrobial drug resistant micro-organisms to humans.
Article 6.9.3.
Responsibilities of the Competent Authority regulatory authorities

Marketing authorisation
The national rThe Regulatory Competent Authority authorities are is responsible for granting marketing authorisation which. This should be done in accordance with the provisions of the Terrestrial Code. It has They have a significant role in specifying the terms of this authorisation and in providing the appropriate information to the veterinarians and all the other relevant stakeholders.
All Member Countries should actively combat the unauthorised manufacture, compounding, importation, advertisement, trade, distribution and use of unlicensed and counterfeit products, including bulk active ingredients, through appropriate regulatory controls and other measures.
Submission of data for the granting of the marketing authorisation
The pharmaceutical industry has to submit the data requested for the granting of the marketing authorisation. The Marketing authorisation is granted on the basis of the data submitted by the pharmaceutical industry or applicant and only if the criteria of safety, quality and efficacy are met. An evaluation assessment of the potential risks and benefits to both animals and humans resulting from the use of antimicrobial agents, with particular focus on use in food-producing animals, should be carried out. The evaluation should focus on each individual antimicrobial agents product and the findings should not be generalised to the class of antimicrobials class to which the particular active ingredient principle belongs. Guidance on usage should be provided for all target species, route of administration, doseage regimens, ranges or withdrawal period and different durations of treatment that are proposed.
Market authorisation approval
The Competent Authority Regulatory authorities should ensure attempt to expedite expedite that the market approval process of a new VMPs containing antimicrobial agent(s) occurs without undue delay in order to address a specific need for the treatment of animal disease.
Registration procedures
The Member Countries lacking the necessary resources to implement an efficient registration procedure for veterinary medicinal products (VMPs), and whose supply principally depends on imports from foreign countries and which are importing VMP, should undertake the following measures: a) check the efficacy of administrative controls on the import of these VMPs; b) check the validity of the registration procedures of the exporting and manufacturing country as appropriate;
c) develop the necessary technical co-operation with experienced authorities to check the quality of imported VMPs as well as the validity of the recommended conditions of use.
The Competent Authorities Regulatory authorities of importing countries should request the pharmaceutical industry to provide quality certificates prepared by the Competent Authority of the exporting and manufacturing country as appropriate. All Member cCountries should make every effort to actively combat the manufacture, advertisement, trade, distribution and use of unlicensed and counterfeit bulk active pharmaceutical ingredients and products including bulk active ingredients. − establish an appropriate dosage regimen (dose, dosing interval and duration of the treatment) and route of administration necessary to ensure the therapeutic efficacy of the antimicrobial agent(s) and limit the selection of antimicrobial resistance. (Pharmacokinetic and pharmacodynamic data and models can assist in this appraisal.).
Quality
ii) The activity of antimicrobial agent(s) towards the targeted micro-organism should be established by pharmacodynamics. The following criteria should be taken into account:
− spectrum of activity and mode of action;
− minimum inhibitory and bactericidal concentrations against recent isolates;
− time-or concentration-dependent activity or co-dependency;
− activity at the site of infection.
iii) The dosage regimens allowing maintenance of effective antimicrobial levels should be established by pharmacokinetics. The following criteria should be taken into account: iii) eligibility of studied clinical cases, based on appropriate criteria of clinical and bacteriological diagnoses;
iv) parameters for qualitatively and quantitatively assessing the efficacy of the treatment.
Assessment of the potential of antimicrobials agent(s) to select for resistance
Other studies may be requested in support of the assessment of the potential of antimicrobials agents to select for resistance (Guidelines providing information for developing such studies are available, e.g. VICH GL-27). The party applying for market authorisation should, where possible, supply data derived in target animal species under the intended conditions of use.
For this the following may be considered: a) the concentration of either active antimicrobial agent(s) or metabolite(s) compound in the gut of the animal (where the majority of potential food-borne pathogens reside) at the defined dosage level; b) pPathway for the human exposure to antimicrobial resistant micro-organsims the route and level of human exposure to food-borne or other resistant organisms; c) the degree of cross-resistance within and between the class of antimicrobials classes and between classes of antimicrobials; d) the intrinsic and pre-existing, baseline level of resistance in the pathogens of human health concern (baseline determination) in both animals and humans.
8. Establishment of acceptable daily intake (ADI), maximum residue level limit (MRL) and withdrawal periods for antimicrobial agents compounds in food producing animals a) When setting the acceptable daily intake (ADI) and MRL for an antimicrobial agents substance, the safety evaluation should also include the potential biological effects on the intestinal flora of humans (Guidelines are available, e.g. VICH GL-33).
b) The establishment of an ADI for each antimicrobial agent, and an MRL for each animal-derived food, should be undertaken. c) For all VMP containing antimicrobial agent(s), withdrawal periods should be established for each animal species in order to ensure produce food in compliance with the MRLs, taking into account:
i) the MRLs established for the antimicrobial agent in the target animal and target edible tissues under consideration;
ii) the composition of the product and the pharmaceutical form;
iii) the target animal species;
iiiiv) the dosage regimen and the duration of treatment;
iv) the route of administration.
d) The applicant should provide methods for regulatory testing of residues in food based on the established marker residues.
Protection of the environment
An assessment of the impact of the proposed antimicrobial use on the environment should be conducted (Guidelines are available, e.g. VICH GL-6 and GL-38). Efforts should be made to ensure that the environmental impact of antimicrobial use is restricted to a minimum.
Establishment of a summary of product characteristics for each veterinary medicinal products containing antimicrobial agent(s) product
The summary of product characteristics contains the information necessary for the appropriate use of VMPs containing veterinary antimicrobial agent(s)product (VAP) and constitutes the official reference for their labelling and package insert. This summary should contain the following items: 
Research
The relevant authorities should encourage public-and industry-funded research, for example on methods to identify and mitigate the public health risks associated with specific antimicrobial agent uses, or on the ecology of antimicrobial resistance.
Article 6.9.4.
Responsibilities of the veterinary pharmaceutical industry with regards to VMP veterinary medicinal products containing antimicrobial agent(s)
Marketing authorisation of VAPs
The veterinary pharmaceutical industry has responsibilities to: a) supply all the information requested by the national Competent Authorityregulatory authorities; b) guarantee the quality of this information in compliance with the provisions of good manufacturing, laboratory and clinical practices; c) implement a pharmacovigilance programme and on request, specific surveillance for bacterial susceptibility and resistance data.
Marketing and export of VAPs
For the marketing and export of VMPs containing antimicrobial agent(s) VAPs: a) only licensed and officially approved VMPs containing antimicrobial agent(s) VAPs should be sold and supplied, and then only through licensed/authorised distribution systems;
b) the pharmaceutical industry should provide quality certificates prepared by the Competent Authority of the exporting and/or manufacturing countries to the importing country; c) the national regulatory authority should be provided with the information necessary to evaluate the amount of antimicrobial agents marketed.
Advertising
The veterinary pharmaceutical industry should respect principles of responsible and prudent use and should comply with established codes of advertising standards, including to: a) distribute disseminate information in compliance with the provisions of the granted authorisation;
b) discourage ensure that the advertising of VMPs containing antimicrobial agent(s) antimicrobials directly to the food animal producer is discouraged.
Training
The veterinary pharmaceutical industry should participate in training programmes as defined in point 14 of Article 6.9.3.
Research
The veterinary pharmaceutical industry should contribute to research as defined in point 15 of Article 6.9.3. Article 6.9.5. 3. Distributors should also be involved in training programmes on the responsible and prudent use of VMPs containing antimicrobials agent(s) antimicrobials, as defined in point 14 of Article 6.9.3. Article 6.9.6.
Responsibilities of wholesale and retail distributors
Responsibilities of veterinarians
The concern of the veterinarian's responsibility is to promote public health, and animal health and welfare., The veterinarian's responsibilities includinge identification preventing, prevention identifying and treatmenting of animal diseases. The promotion of sound animal husbandry methods, hygiene procedures, biosecurity and vaccination strategies (good farming practice) can help to minimise the need for antimicrobial use in foodproducing animals.
Veterinarians should only prescribe antimicrobial agent(s) for animals under their care.
Use of antimicrobial agent(s)
The ii) diagnostic laboratory information (pathogen isolation, identification and antibiogram)
iii) known pharmacodynamics including the activity towards the pathogens involved;
ivii) the appropriate dosage regimen and route of administration; iv) known pharmacokinetics and/ tissue distribution to ensure that the selected therapeutic agent is active effective at the site of infection;
vi) the epidemiological history of the rearing unit, particularly in relation to the antimicrobial resistance profiles of the pathogens involved.
Should a first-line antimicrobial treatment fail or should the disease recur, a second line treatment should ideally be based on the results of diagnostic tests. In the absence of such results, an appropriate antimicrobial agent belonging to a different class or sub-class should be used.
To minimise the likelihood of antimicrobial resistance developing in target or other organisms, it is recommended that antimicrobials agents be targeted to pathogens likely to be the cause of infection.
On certain occasions, a group of animals that may have been exposed to pathogens may need to be treated without recourse to an accurate diagnosis and antimicrobial susceptibility testing to prevent the development of clinical disease and for reasons of animal welfare.
b) Use of combinations of antimicrobials agents should be scientifically supported. Combinations of antimicrobials agents may be used for their synergistic effect to increase therapeutic efficacy or to broaden the spectrum of activity.
Appropriate use of the VMPs containing antimicrobial agent(s) chosen
A prescription for VMPs containing antimicrobial agent(s) antimicrobial agents should indicate precisely the treatment dosage regimen, the dose, the treatment intervals, the duration of the treatment, the withdrawal period where applicable and the amount of VMPs drug to be provided delivered, depending on the dosage and the number of animals to be treated.
The extra-label or off-label use of a veterinary VMPs containing antimicrobial agent(s) drug may be permitted in appropriate circumstances and should be in agreement with the national legislation in force including the withdrawal periods to be used, as applicable. It is the veterinarian's responsibility to define the conditions of responsible use in such a case including the dosage regimen, and therapeutic regimen, the route of administration and the withdrawal period, and the duration of the treatment. Veterinarians should also periodically review farm records on the use of VMAPs containing antimicrobial agent(s) to ensure compliance with their directions/ or prescriptions and use these records to evaluate the efficacy of treatments regimens.
Labelling
All medicines VMPs supplied by a veterinarian should be labelled according to the national legislation.
Training/ and continued professional development
Veterinary professional organisations should participate in the training programmes as defined in point 14 of Article 6.9.3. It is recommended that veterinary professional organisations develop for their members species-specific clinical practice recommendations on the responsible and prudent use of VMAPs containing antimicrobial agent(s) (e.g. Guidelines for the judicious use of antimicrobials in various animal species developed by the American Veterinary Medical Association).
Article 6.9.7.
Responsibilities of food-animal producers
1. Food-animal producers, with the assistance and guidance of a veterinarian, are responsible for implementing animal health and welfare programmes on their farms (good farming practice) in order to promote animal health and food safety. jk) inform the responsible veterinarian of recurrent disease problems.
Food
Training
Food-animal producers should participate in the training programmes as defined in Point 14 of Article 6.9.3. It is recommended that food-animal producer organisations work in cooperation with the veterinary professional organisations to implement existing guidelines for the responsible and prudent use of VMPs containing antimicrobial agent(s).
Article 6.9.8.
Responsibilities of animal feed manufacturers
1. Animal feed manufacturers preparing medicated feeds should do so only on the prescription of a veterinarian or other suitably trained person authorised to prescribe VMP containing antimicrobial agent(s) in accordance with the national legislation and under the supervision of a veterinarian. All products should be appropriately labelled.
2. The regulations and recommendations on the responsible and prudent use of VMP containing antimicrobial agent(s) should be reinforced by animal feed manufacturers who should keep detailed records as noted in Article 6.9.5.
Use only approved sources of medications:
Animal feed manufacturers preparing medicated feeds should ensure that only approved sources of medications are added to feeds at a level, purpose and species as permitted by the drug premix label or a veterinary prescription.
